A therapeutic role for a regulatory GLUT1–associated lncRNA in GLUT1-deficient mice
Authors:
- Maoxue TangMTMaoxue Tang
- Sasa TengSTSasa Teng
- Yueqing PengYPYueqing Peng
- Ashley Y. KimAKAshley Y. Kim
- Yoon-Ra HerYHYoon-Ra Her
- Peter CanollPCPeter Canoll
- Jeffrey N. BruceJBJeffrey N. Bruce
- Phyllis L. FaustPFPhyllis L. Faust
- Kailash AdhikariKAKailash Adhikari
- Darryl C. De VivoDVDarryl C. De Vivo
- Umrao R. MonaniUMUmrao R. Monani
Open Access
- 5 March 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Abstract
The mammalian brain relies primarily on glucose for its energy needs. Delivery of this nutrient to the brain is mediated by the glucose transporter-1 (GLUT1) protein. Low GLUT1 thwarts glucose entry into the brain, causing an energy crisis and triggering, in one instance, the debilitating neurodevelopmental condition known as GLUT1 deficiency syndrome (GLUT1DS). Current treatments for GLUT1DS are suboptimal, as none address the root cause — low GLUT1 — of the condition. Levels of this transporter must respond rapidly to the brain’s changing energy requirements. This necessitates fine tuning its expression. Here, we describe a long-noncoding RNA (lncRNA) antisense to GLUT1 (SLC2A1) and show that it is involved in such regulation. Raising levels of the lncRNA had a concordant effect on GLUT1 in cultured human cells and transgenic mice; reducing levels elicited the opposite effect. Delivering the lncRNA to GLUT1DS model mice via viral vectors induced GLUT1 expression, enhancing brain glucose levels to mitigate disease. Direct delivery of such a lncRNA to combat disease has not been reported previously and constitutes, to our knowledge, a unique therapeutic paradigm. Moreover, considering the importance of maintaining homeostatic GLUT1 levels, calibrating transporter expression via the lncRNA could become broadly relevant to myriad conditions, including Alzheimer’s disease, wherein GLUT1 is perturbed.Keywords
Funding Information
- National Institutes of Health (R03 NS128211)
- National Institutes of Health (P30 CA013696)
This publication has 56 references indexed in Scilit:
- Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain – a reviewEuropean Journal of Pediatrics, 2002
- GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrierNature Genetics, 1998
- Structure of the human alpha 2 subunit gene of the glycine receptor--use of vectorette and Alu-exon PCR.Genome Research, 1996
- Developmental Expression of GLUT1 and GLUT3 Glucose Transporters in Rat BrainJournal of Neurochemistry, 1994
- Defective Glucose Transport across the Blood-Brain Barrier as a Cause of Persistent Hypoglycorrhachia, Seizures, and Developmental DelayNew England Journal of Medicine, 1991
- A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clonesNucleic Acids Research, 1990
- Reduced Glucose Transporter at the Blood‐Brain Barrier and in Cerebral Cortex in Alzheimer DiseaseJournal of Neurochemistry, 1989
- Disordered mineral metabolism produced by ketogenic diet therapyCalcified Tissue International, 1979
- The Clinical and Biochemical Implications of Pyruvate Carboxylase DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 1977
- Ketotic hypoglycemia and the ketogenic dietNeurology, 1973